Evidence map›Paper›PMID 34452557›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Prognostic Significance of Tripartite Motif Containing 16 Expression in Patients with Gastric Cancer.

Jalil Afshar, Jamshid Mehrzad, Hassan Mehrad-Majd, Ladan Goshayeshi, Jafar Saeidi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Multifaceted role ofMedComm · 2024
    Review
  4. Review
  5. Article
  6. Clinical Significance of TRIM44 Expression in Patients with Gastric Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022
    Article
  7. Clinical significance of TRIM29 expression in patients with gastric cancer.Gastroenterology and hepatology from bed to bench · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jalil AfsharDepartment of Biochemistry, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran.
Jamshid MehrzadDepartment of Biochemistry, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran.ORCID 0000-0001-8700-3914
Hassan Mehrad-MajdCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ladan GoshayeshiDepartment of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Jafar SaeidiDepartment of Physiology, School of Basic Science, Neyshabur Branch, Islamic Azad University, Neyshabur, Iran.
Mashhad University of Medical Sciences · IRUniversity of Neyshabur · IRIslamic Azad University, Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimTripartite Motif Containing 16 (TRIM16) is a member of the TRIM protein family which is known to play a suppressor role in development of numerous tumor types. However, a positive correlation between TRIM16 expression and gastric cancer (GC) progress has created a controversial situation that need to be fully delineated.  The aim of this study was to assess the expression level of TRIM16 mRNA and its relationship with β-catenin, CyclinD, and BCL2 expression in Iranian GC patients and to investigate its possible association with patients' overall survival.  Materials and Methods: The expression level of TRIM16 of fresh primary tumor and adjacent normal tissues in 40 GC patients was evaluated by real-time quantitative PCR method. Moreover, patients were subdivided into high or low expression subgroups based on the TRIM16 expression levels. The relationship between TRIM16 expression level, β-catenin, Cyclin D, BCL2, some clinicopathological data and prognosis of GC patients was also analyzed.

resultsqPCR analysis showed a lower level of TRIM16 in GC tissues (fold change=0.351) in comparison to their matched adjacent noncancerous tissues (p <0.001). Contrary to this, the expression levels of β-catenin, Cyclin D, and BCL2 genes were up-regulated in cancerous samples. This may explain the tumor suppressive function of TRIM16 in GC; as reduction in TRIM16 expression leads to the accumulation of mRNAs from β-catenin, Cyclin D, and BCL2 genes and eventually cancer progression. We did not observe any significant correlation between TRIM16 expression and patients' overall survival. Univariate Cox regression analysis indicated that anemia, weight loss, bleeding, stomach ache, and smoking are statistically associated with overall survival; while, multivariate analysis did not support any correlation.  Conclusions: In sum, this study suggests a tumor suppressive role for TRIM16 in gastric cancer and proposes it as a potential candidate for GC prognosis.<br />.

Indexed as

AgedBiomarkers, TumorCase-Control StudiesFemaleFollow-Up StudiesHumansMalePrognosisStomach NeoplasmsSurvival RateTripartite Motif ProteinsUbiquitin-Protein LigasesBiomarkers, TumorTRIM16 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesOverall survivalTRIM16tripartite motif-containing 16, gastric cancer

Identifiers

PMID34452557
PMCPMC8629450
OpenAlexW3195807781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.